Supplementary Online Content


**eFigure 1.** Funnel plots of studies comparing ACEIs with controls on all-cause mortality
**eFigure 2.** Funnel plots of studies comparing ACEIs with controls on CV deaths
**eFigure 3.** Funnel plots of studies comparing ARBs with controls on all-cause mortality
**eFigure 4.** Funnel plots of studies comparing ARBs with controls on CV deaths
**eFigure 5.** ACEIs and CV events stratified by comparison group (placebo vs active)
**eFigure 6.** ARBs and CV events stratified by comparison group (placebo vs active)

This supplementary material has been provided by the authors to give readers additional information about their work.
eFigure 1. Funnel plots of studies comparing ACEIs with controls on all-cause mortality. SE, standard error; OR, odds ratio
**eFigure 2.** Funnel plots of studies comparing ACEIs with controls on CV deaths. SE, standard error; OR, odds ratio
eFigure 3. Funnel plots of studies comparing ARBs with controls on all-cause mortality. SE, standard error; OR, odds ratio
eFigure 4. Funnel plots of studies comparing ARBs with controls on CV deaths. SE, standard error; OR, odds ratio
### eFigure 5. ACEIs and CV events stratified by comparison group (placebo vs active)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>ACE inhibitors better</th>
<th>Control better</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADVANCE study</td>
<td>468</td>
<td>5569</td>
<td>535</td>
<td>5571</td>
</tr>
<tr>
<td>DIABHYCAR study</td>
<td>465</td>
<td>2443</td>
<td>518</td>
<td>2469</td>
</tr>
<tr>
<td>HOPE study</td>
<td>277</td>
<td>1808</td>
<td>351</td>
<td>1769</td>
</tr>
<tr>
<td>PERSUADE substudy</td>
<td>91</td>
<td>721</td>
<td>121</td>
<td>781</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>10541</td>
<td>10590</td>
<td>51.6%</td>
<td></td>
</tr>
<tr>
<td>Total events</td>
<td>1301</td>
<td>1525</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.00; Chi² = 3.30, df = 3 (P = 0.35); I² = 9%
Test for overall effect: Z = 4.20 (P < 0.0001)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>ACE inhibitors better</th>
<th>Control better</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>Active</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABCD study</td>
<td>15</td>
<td>235</td>
<td>38</td>
<td>235</td>
</tr>
<tr>
<td>ALLHAT study</td>
<td>568</td>
<td>3510</td>
<td>970</td>
<td>5994</td>
</tr>
<tr>
<td>CAPPP study</td>
<td>54</td>
<td>309</td>
<td>63</td>
<td>263</td>
</tr>
<tr>
<td>FACET study</td>
<td>14</td>
<td>189</td>
<td>27</td>
<td>191</td>
</tr>
<tr>
<td>Fagard2002</td>
<td>7</td>
<td>102</td>
<td>8</td>
<td>103</td>
</tr>
<tr>
<td>J-MIND study</td>
<td>8</td>
<td>208</td>
<td>5</td>
<td>228</td>
</tr>
<tr>
<td>JMIC-B study</td>
<td>16</td>
<td>173</td>
<td>19</td>
<td>199</td>
</tr>
<tr>
<td>Nielsen1997</td>
<td>1</td>
<td>17</td>
<td>9</td>
<td>19</td>
</tr>
<tr>
<td>STOP -2 substudy</td>
<td>67</td>
<td>235</td>
<td>82</td>
<td>253</td>
</tr>
<tr>
<td>UKPDS 39 study</td>
<td>94</td>
<td>400</td>
<td>72</td>
<td>358</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>5378</td>
<td>7843</td>
<td>48.4%</td>
<td></td>
</tr>
<tr>
<td>Total events</td>
<td>844</td>
<td>1293</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.05; Chi² = 24.34, df = 9 (P = 0.004); I² = 63%
Test for overall effect: Z = 1.70 (P = 0.09)

Total (95% CI) 15919 18433 100.0% 0.86 [0.77, 0.95]
Total events 2145 2818
Heterogeneity: Tau² = 0.02; Chi² = 31.58, df = 13 (P = 0.003); I² = 59%
Test for overall effect: Z = 2.82 (P = 0.005)
<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Experimental Events</th>
<th>Control Total Events</th>
<th>Total Events</th>
<th>Weight M-H Random 95% CI</th>
<th>Risk Ratio M-H Random 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IDNT(Placebo) study</td>
<td>172</td>
<td>579</td>
<td>185</td>
<td>567</td>
<td>14.2%</td>
</tr>
<tr>
<td>IRMA study</td>
<td>9</td>
<td>194</td>
<td>18</td>
<td>201</td>
<td>0.9%</td>
</tr>
<tr>
<td>ORIENT study</td>
<td>40</td>
<td>288</td>
<td>53</td>
<td>289</td>
<td>3.5%</td>
</tr>
<tr>
<td>PROFESSION study</td>
<td>528</td>
<td>2804</td>
<td>543</td>
<td>2903</td>
<td>28.0%</td>
</tr>
<tr>
<td>RENAAL Study</td>
<td>247</td>
<td>751</td>
<td>268</td>
<td>762</td>
<td>19.5%</td>
</tr>
<tr>
<td>ROADMAP study</td>
<td>96</td>
<td>2232</td>
<td>94</td>
<td>2215</td>
<td>6.2%</td>
</tr>
<tr>
<td>SCOPE study</td>
<td>46</td>
<td>313</td>
<td>51</td>
<td>286</td>
<td>3.7%</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>7161</td>
<td>7223</td>
<td>75.9%</td>
<td>0.95 [0.88, 1.02]</td>
<td></td>
</tr>
</tbody>
</table>

Total events: 1138 1212
Heterogeneity: Tau² = 0.00; Chi² = 5.92, df = 6 (P = 0.43); I² = 0%
Test for overall effect: Z = 1.43 (P = 0.15)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Experimental Events</th>
<th>Control Total Events</th>
<th>Total Events</th>
<th>Weight M-H Random 95% CI</th>
<th>Risk Ratio M-H Random 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CASE-J study</td>
<td>31</td>
<td>1011</td>
<td>36</td>
<td>1007</td>
<td>2.3%</td>
</tr>
<tr>
<td>IDNT(Active) study</td>
<td>172</td>
<td>579</td>
<td>161</td>
<td>567</td>
<td>13.1%</td>
</tr>
<tr>
<td>LIFE study</td>
<td>103</td>
<td>586</td>
<td>139</td>
<td>609</td>
<td>8.8%</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>2176</td>
<td>2183</td>
<td>24.1%</td>
<td>0.90 [0.72, 1.13]</td>
<td></td>
</tr>
</tbody>
</table>

Total events: 306 336
Heterogeneity: Tau² = 0.02; Chi² = 4.37, df = 2 (P = 0.11); I² = 54%
Test for overall effect: Z = 0.92 (P = 0.36)

Total (95% CI): 9337 9406 100.0% 0.94 [0.87, 1.01]

Total events: 1444 1548
Heterogeneity: Tau² = 0.00; Chi² = 10.40, df = 9 (P = 0.32); I² = 13%
Test for overall effect: Z = 1.82 (P = 0.07)
P=0.33 for interaction

**eFigure 6. ARBs and CV events stratified by comparison group (placebo vs active)**

© 2014 American Medical Association. All rights reserved. 7